Literature DB >> 1723533

Morphologic and immunohistochemical characterization of Leydig cell tumor variants in Wistar rats.

S R Qureshi1, E Perentes, R A Ettlin, M Kolopp, D E Prentice, A Frankfurter.   

Abstract

During a routine long-term drug safety study, lasting approximately 2 1/2 yr, male Wistar rats, treated with a prolactin-inhibiting compound, developed an excess of Leydig cell tumors (LCTs). Most tumors were typical for the rat but a small number showed an unusual variation and some appeared malignant. The variation consisted of glandular and/or tubular structures within the tumor mass which occasionally anastomosed and contained an eosinophilic periodic-acid Schiff (PAS) positive material. In a few of these variants, malignant features such as cellular atypia, capsular, and lymphatic invasion and necrosis were seen. No metastases were detected. Detailed morphological and immunohistochemical investigations were conducted in order to establish the cell of origin of these variants. Glandular/tubular structures were found to stain with varying intensity for vimentin and cytokeratin, but were always negative for beta-tubulin. The results indicated that the cell of origin of these LCT variants was indeed the Leydig cell and that glandular and/or tubular structures within LCTs represented a form of Leydig cell metaplasia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1723533     DOI: 10.1177/019262339101900311

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  5 in total

Review 1.  A brief review of modern toxicologic pathology in regulatory and explanatory toxicity studies of chemicals.

Authors:  R A Ettlin; M Oberholzer; E Perentes; B Ryffel; M Kolopp; S R Qureshi
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

2.  Neuron-associated class III beta-tubulin isotype, retinal S-antigen, synaptophysin, and glial fibrillary acidic protein in human medulloblastomas: a clinicopathological analysis of 36 cases.

Authors:  T Maraziotis; E Perentes; E Karamitopoulou; Y Nakagawa; E C Gessaga; A Probst; A Frankfurter
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

3.  Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings.

Authors:  Robert A Ettlin; Junji Kuroda; Stephanie Plassmann; David E Prentice
Journal:  J Toxicol Pathol       Date:  2010-12-16       Impact factor: 1.628

4.  Successful drug development despite adverse preclinical findings part 2: examples.

Authors:  Robert A Ettlin; Junji Kuroda; Stephanie Plassmann; Makoto Hayashi; David E Prentice
Journal:  J Toxicol Pathol       Date:  2010-12-16       Impact factor: 1.628

5.  Coexpression of multiple Sertoli cell and Leydig cell marker genes in the spontaneous testicular tumor of F344 rat: evidence for phenotypical bifurcation of the interstitial cell tumor.

Authors:  G Kondoh; K Yomogida; K Dohmae; M Nozawa; M Koga; N Nonomura; T Miki; A Okuyama; Y Nishimune
Journal:  Jpn J Cancer Res       Date:  1997-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.